| SC-560 Inhibition, SEM (%) | Celecoxib Inhibition, SEM (%) | p-value |
---|
CRN-pts (N/n = 15/26) | 68.8 ± 4.5 | 53.7 ± 5.1 | 0.035* |
Ctrls (N/n = 10/19) | 80.6 ± 4.8 | 52.6 ± 10.3 | 0.028* |
p-value | 0.10 | 0.91 | |
- Horizontal p-values to the right show inhibition by SC-560 compared to inhibition by Celecoxib for CRN-pts and ctrls. Vertical p-values at the bottom show CRN-pts compared to ctrls for SC-560 inhibition and Celecoxib inhibition. Inhibition calculated as percentage selective COX-inhibition of total COX-inhibition. Total COX-inhibition defined as selective COX-inhibition + indomethacin inhibition. Percentage drop reflects the overall decreased activity. CRN-pts represent values for biopsies from colorectal neoplasia patients and ctrls values are for biopsies from patients without colorectal neoplasia. N = number of patients, n = number of biopsies, in parenthesis (N/n). * p-value < 0.05